Literature DB >> 11212110

Conformational study of a highly specific CXCR4 inhibitor, T140, disclosing the close proximity of its intrinsic pharmacophores associated with strong anti-HIV activity.

H Tamamura1, M Sugioka, Y Odagaki, A Omagari, Y Kan, S Oishi, H Nakashima, N Yamamoto, S C Peiper, N Hamanaka, A Otaka, N Fujii.   

Abstract

We report the solution structure of T140, a truncated polyphemusin peptide analogue that efficiently inhibits infection of target cells by T-cell line-tropic strains of HIV-1 through its specific binding to a chemokine receptor, CXCR4. Nuclear magnetic resonance analysis and molecular dynamic calculations revealed that T140 has a rigidly structured conformation constituted by an antiparallel beta-sheet and a type II' beta-turn. A protuberance is formed on one side of the beta-sheet by the side-chain functional groups of the three amino acid residues (L-3-(2-naphthyl)alanine, Tyr5 and Arg14), each of which is indispensable for strong anti-HIV activity. These findings provide a rationale to dissect the structural basis for the ability of this compound to block the interaction between CXCR4 and envelope glycoproteins from T-tropic strains of HIV-1.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11212110     DOI: 10.1016/s0960-894x(00)00664-8

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  9 in total

1.  Improved guanide compounds which bind the CXCR4 co-receptor and inhibit HIV-1 infection.

Authors:  Royce A Wilkinson; Seth H Pincus; Kejing Song; Joyce B Shepard; Alan J Weaver; Mohamed E Labib; Martin Teintze
Journal:  Bioorg Med Chem Lett       Date:  2013-01-30       Impact factor: 2.823

2.  Synthesis and evaluation of a bimodal CXCR4 antagonistic peptide.

Authors:  Joeri Kuil; Tessa Buckle; Hushan Yuan; Nynke S van den Berg; Shinya Oishi; Nobutaka Fujii; Lee Josephson; Fijs W B van Leeuwen
Journal:  Bioconjug Chem       Date:  2011-04-19       Impact factor: 4.774

Review 3.  Molecular pathogenesis of bone metastases in breast cancer: Proven and emerging therapeutic targets.

Authors:  Nadia Rucci; Patrizia Sanità; Simona Delle Monache; Edoardo Alesse; Adriano Angelucci
Journal:  World J Clin Oncol       Date:  2014-08-10

Review 4.  Peptide and protein-based inhibitors of HIV-1 co-receptors.

Authors:  Horst A von Recum; Jonathan K Pokorski
Journal:  Exp Biol Med (Maywood)       Date:  2013-05

5.  Structural characterization and in vivo evaluation of β-Hairpin peptidomimetics as specific CXCR4 imaging agents.

Authors:  Wojciech G Lesniak; Emilia Sikorska; Hassan Shallal; Babak Behnam Azad; Ala Lisok; Mrudula Pullambhatla; Martin G Pomper; Sridhar Nimmagadda
Journal:  Mol Pharm       Date:  2015-02-03       Impact factor: 4.939

6.  Novel compounds containing multiple guanide groups that bind the HIV coreceptor CXCR4.

Authors:  Royce A Wilkinson; Seth H Pincus; Joyce B Shepard; Sarah K Walton; Edward P Bergin; Mohamed Labib; Martin Teintze
Journal:  Antimicrob Agents Chemother       Date:  2010-10-11       Impact factor: 5.191

Review 7.  Chemokine receptor CXCR4 as a therapeutic target for neuroectodermal tumors.

Authors:  Hyunsuk Shim; Shinya Oishi; Nobutaka Fujii
Journal:  Semin Cancer Biol       Date:  2008-11-25       Impact factor: 15.707

Review 8.  Structure-Based Design of Inhibitors of Protein-Protein Interactions: Mimicking Peptide Binding Epitopes.

Authors:  Marta Pelay-Gimeno; Adrian Glas; Oliver Koch; Tom N Grossmann
Journal:  Angew Chem Int Ed Engl       Date:  2015-06-26       Impact factor: 15.336

9.  Exploratory studies on development of the chemokine receptor CXCR4 antagonists toward downsizing.

Authors:  Hirokazu Tamamura; Hiroshi Tsutsumi; Wataru Nomura; Nobutaka Fujii
Journal:  Perspect Medicin Chem       Date:  2008-02-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.